Collegium Pharmaceutical Inc (NASDAQ:COLL) Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $15.56, for a total value of $389,000.00. Following the transaction, the director now owns 286,000 shares of the company’s stock, valued at approximately $4,450,160. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Thomas Heffernan also recently made the following trade(s):

  • On Monday, December 17th, Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $18.18, for a total value of $454,500.00.
  • On Thursday, November 15th, Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $16.60, for a total value of $415,000.00.

Shares of COLL stock traded up $0.16 during mid-day trading on Thursday, hitting $16.04. The company’s stock had a trading volume of 168,900 shares, compared to its average volume of 573,758. Collegium Pharmaceutical Inc has a 52-week low of $13.70 and a 52-week high of $29.90. The company has a debt-to-equity ratio of 4.17, a current ratio of 0.78 and a quick ratio of 0.75. The stock has a market capitalization of $519.99 million, a P/E ratio of -6.49 and a beta of 0.52.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The business had revenue of $70.20 million during the quarter, compared to analysts’ expectations of $74.79 million. During the same quarter in the prior year, the firm earned ($0.45) EPS. The firm’s revenue for the quarter was up 485.0% compared to the same quarter last year. As a group, analysts anticipate that Collegium Pharmaceutical Inc will post -1.85 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Collegium Pharmaceutical by 11.5% in the second quarter. Rhumbline Advisers now owns 28,341 shares of the specialty pharmaceutical company’s stock worth $676,000 after purchasing an additional 2,916 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Collegium Pharmaceutical by 644.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after acquiring an additional 3,179 shares during the period. Teachers Advisors LLC grew its holdings in shares of Collegium Pharmaceutical by 6.2% in the third quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after acquiring an additional 4,484 shares during the period. Raymond James & Associates grew its holdings in shares of Collegium Pharmaceutical by 24.2% in the second quarter. Raymond James & Associates now owns 27,847 shares of the specialty pharmaceutical company’s stock worth $664,000 after acquiring an additional 5,434 shares during the period. Finally, Monarch Partners Asset Management LLC grew its holdings in shares of Collegium Pharmaceutical by 26.9% in the third quarter. Monarch Partners Asset Management LLC now owns 28,340 shares of the specialty pharmaceutical company’s stock worth $418,000 after acquiring an additional 6,000 shares during the period.

A number of research analysts have issued reports on the company. Cantor Fitzgerald set a $35.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Friday, September 21st. BidaskClub upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 4th. ValuEngine cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, January 7th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research note on Wednesday, January 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective (down previously from $35.00) on shares of Collegium Pharmaceutical in a research note on Wednesday. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Collegium Pharmaceutical has an average rating of “Buy” and a consensus price target of $30.14.

ILLEGAL ACTIVITY NOTICE: “Collegium Pharmaceutical Inc (COLL) Director Michael Thomas Heffernan Sells 25,000 Shares” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-director-michael-thomas-heffernan-sells-25000-shares-2/2753519.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Article: What is the quiet period?

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.